Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline—Results From a Randomized Controlled Clinical Trial

Introduction: Previous research delivers strong indications that inflammatory activation leads to treatment resistance in a subgroup of patients with Major Depressive Disorder (MDD). Thus, tailored interventions are needed. The present study aimed to find potential biomarkers that may enable patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Maria S., Burger, Bianka, Weidinger, Elif, Arteaga-Henríquez, Gara, Zill, Peter, Musil, Richard, Drexhage, Hemmo A., Müller, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504576/
https://www.ncbi.nlm.nih.gov/pubmed/34646168
http://dx.doi.org/10.3389/fpsyt.2021.615261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504576/
https://www.ncbi.nlm.nih.gov/pubmed/34646168
http://dx.doi.org/10.3389/fpsyt.2021.615261

Ejemplares similares